Evidence map›Paper›PMID 39066440›Full record

ArticleVaccines2024

Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines.

Matthew D Rousculp, Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Hadi Beyhaghi, Seth Toback

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew D RousculpNovavax, Inc., Gaithersburg, MD 20878, USA.ORCID 0009-0001-2509-1098
Kelly HollisRTI Health Solutions, Research Triangle Park, NC 27709, USA.
Ryan ZiemieckiRTI Health Solutions, Research Triangle Park, NC 27709, USA.
Dawn OdomRTI Health Solutions, Research Triangle Park, NC 27709, USA.
Anthony M MarcheseNovavax, Inc., Gaithersburg, MD 20878, USA.
Mitra MontazeriNovavax, Inc., Gaithersburg, MD 20878, USA.
Shardul OdakRTI Health Solutions, Research Triangle Park, NC 27709, USA.
Laurin JacksonRTI Health Solutions, Research Triangle Park, NC 27709, USA.
Hadi BeyhaghiNovavax, Inc., Gaithersburg, MD 20878, USA.
Seth TobackNovavax, Inc., Gaithersburg, MD 20878, USA.ORCID 0000-0002-5838-812X

Funding

Novavax (United States) N/A
6 · The paper itself

Abstract

Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational 2019nCoV-406 study was conducted to examine reactogenicity within the first 2 days after vaccination with either a protein-based vaccine (NVX-CoV2373) or an mRNA vaccine (BNT162b2 or mRNA-1273) in individuals who previously completed a primary series. Propensity score adjustments were conducted to address potential confounding. The analysis included 1130 participants who received a booster dose of NVX-CoV2373 (

Indexed as

boosterCOVID-19mRNANVX-CoV2373reactogenicityreal-world evidenceSARS-CoV-2

Identifiers

PMID39066440
PMCPMC11281689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.